Fierce Pharma
FEBRUARY 2, 2024
Mark your calendars, oncology drug and CAR-T therapy developers. | Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting for Bristol Myers' Abecma and J&J's Carvykti.
MedCity News
FEBRUARY 2, 2024
A new era in maternal care is emerging with the advent of maternity care management platforms. Innovative organizations are centralizing the coordination of all patient care aspects, seamlessly integrating with providers’ electronic health records, existing workflows, and health information exchanges.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 2, 2024
As AbbVie slogs through sharp revenue declines for Humira, the company is looking to the immunology light at the end of the tunnel. | Sales of Humira—which once sat pretty as the world’s best-selling drug—plunged nearly 41% to $3.3 billion in the third quarter.
Pharmaceutical Commerce
FEBRUARY 2, 2024
A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 2, 2024
In his first earnings call as Bristol Myers Squibb’s CEO, Chris Boerner laid out his plan to quickly navigate the company through a period filled with patent cliffs and new government-man | In his first earnings call as Bristol Myers Squibb’s CEO, Chris Boerner laid out his plan to quickly navigate the company through a transition period filled with patent cliffs and new government-mandated pricing pressure.
MedCity News
FEBRUARY 2, 2024
Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company’s two most advanced programs are depression drugs in mid-stage development.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 2, 2024
Adapting to healthcare consumerism is vital for providers to stay competitive. Shifting from traditional roles to informed consumers requires embracing transparency, technology, and personalized care.
European Pharmaceutical Review
FEBRUARY 2, 2024
Orano Med (a subsidiary of the Orano Group), has begun to build a new manufacturing site for targeted alpha therapies (TAT) for oncology indications. The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. TAT [targeted alpha therapies] is one of the most potent therapeutic payloads against cancer cells” According to Orano Med, TAT is “one of the most potent therapeutic payloads against cancer cells” As such, these trea
MedCity News
FEBRUARY 2, 2024
Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.
European Pharmaceutical Review
FEBRUARY 2, 2024
A study has described a multivalent-colloid detection system capable of identifying whole genomes of bacteria without the use of DNA amplification. Data from the paper published in Applied Physical Sciences , showed that the method can detect pathogens at an early stage when the bacterial load is low. Currently, the “gold standard” of pathogen identification is based on the recognition of DNA sequences that are unique for a given pathogen, according to the authors.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
FEBRUARY 2, 2024
Foodsmart is rolling out its new program that enables doctors to refer their patients to Foodsmart’s dieticians and healthy eating platform, as well as write prescriptions for healthy food just as easily as they might a normal pharmacy prescription. The initiative is being rolled out at Advocate Health, Intermountain Health and Memorial Hermann Health System.
European Pharmaceutical Review
FEBRUARY 2, 2024
Biogen is planning to reprioritise its resources allocated to ADUHELM ® (aducanumab-avwa), to advance its Alzheimer’s treatment LEQEMBI ® (lecanemab-irmb) and to develop new treatment modalities. The company stated that it will discontinue the development and commercialisation of ADUHELM 100 mg/mL intravenous injection and will terminate the corresponding Phase III ENVISION clinical study.
MedCity News
FEBRUARY 2, 2024
It is critical that we rightsize and redistribute available funds based on our knowledge of persistent cancer disparities to help more patients benefit from potentially lifesaving innovations and ensure no one is left behind.
PharmaVoice
FEBRUARY 2, 2024
Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
FEBRUARY 2, 2024
Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T specialist Kyverna and private rounds for Eyconis, COUR Pharmaceuticals, Basking Biosciences, Enterprise Therapeutics, Halia Therapeutics and NeoPhore.
Copyright Clearance Center
FEBRUARY 2, 2024
The post CCC President & CEO Tracey Armstrong Wins 2024 BIG Innovation Award appeared first on Copyright Clearance Center.
pharmaphorum
FEBRUARY 2, 2024
Indian pharma Hikma has agreed a $150 million settlement to resolve lawsuits claiming that it helped fuel to the opioid crisis in the US
PharmaTech
FEBRUARY 2, 2024
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
pharmaphorum
FEBRUARY 2, 2024
The PM Society are delighted to be running their fifth Careers Conference that will be taking place on the 21st of February 2024 between 1pm to 6pm at the Royal Society of Medicine. Please share with your colleagues and network, as this is a great opportunity for students to attend and learn more about our industry.
MedCity News
FEBRUARY 2, 2024
Accompany Health launched Tuesday with $56 million in Series A funding. It offers primary and behavioral care for underserved patients. It also provides social care, such as food, housing and transportation assistance.
Pharmaceutical Commerce
FEBRUARY 2, 2024
Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.
Pharmaceutical Technology
FEBRUARY 2, 2024
The US FDA has granted rare paediatric disease (RPD) designation for Tyra Biosciences’ TYRA-300 for treating achondroplasia.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
FEBRUARY 2, 2024
Virtual opioid use disorder (OUD) therapy provider Bicycle Health has teamed up with telemedicine specialist Talkspace to expand access to care for patients battling addiction in the US. Bicycle Health provides medication for OUD treatment, drug screening, behavioural therapy, and peer support via an app that has been used by tens of thousands of people across the US.
PharmaTimes
FEBRUARY 2, 2024
Dopamine neuron senescence is a hallmark of Parkinson’s disease
pharmaphorum
FEBRUARY 2, 2024
The FDA is due to decide by 4th August whether to approve Adaptimmune’s afami-cel engineered T-cell therapy for advanced synovial sarcoma.
PharmaTimes
FEBRUARY 2, 2024
Individuals with Jewish ancestry are six times more likely to carry a genetic fault
pharmaphorum
FEBRUARY 2, 2024
The World Health Organization (WHO) has said that the burden of cancer on societies around the world is growing at an alarming rate, with a 77% increase in new cases expected by 2050, along with significant gaps in care.
MedCity News
FEBRUARY 2, 2024
One new solution that’s becoming an emerging standard is the Health Payment Account (HPA). HPAs offer employees a line of interest-free credit that employees can use to pay for care expenses up-front.
Pharmaceutical Commerce
FEBRUARY 2, 2024
New reservation program for Beyfortus (nirsevimab-alip) seeks to improve access to the monoclonal antibody that is FDA-approved to protect against respiratory syncytial virus-associated lower respiratory tract disease.
PharmExec
FEBRUARY 2, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, provides her thoughts on the success of the trial.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
321 
Let's personalize your content